GlassScriptPhysician profile
David M Krasner
NPI 1629017447
$15,511.04
in general payments reported to CMS, 2019-2025
49 companies · $2,991 in 2025
The $2,991 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,040 · 2020: $1,864 · 2021: $1,671 · 2022: $2,663 · 2023: $1,292 · 2024: $2,991 · 2025: $2,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153 · Consulting Fee: $1,740 · Travel and Lodging: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.17 |
| Consulting Fee | $1,740.00 |
| Travel and Lodging | $1,380.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,071.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $2,009.28 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,438.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,425.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,042.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $721.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $622.13 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.36 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $514.98 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $415.74 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $355.86 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $291.46 | 2019-2022 | |
| Exact Sciences Corporation | $187.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $152.81 | 2019-2021 | |
| Abbvie INC. | $147.12 | 2021-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $142.31 | 2019-2020 | |
| Esperion Therapeutics, INC. | $140.80 | 2020-2025 | Nexletol |
| Abbott Laboratories | $112.88 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $105.72 | 2024-2025 | Omnipod |
| Amarin Pharma, INC. | $84.27 | 2019-2020 | |
| Lundbeck LLC | $76.54 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $73.13 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $66.11 | 2020-2021 | |
| Shield Therapeutics INC | $64.48 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $55.51 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $53.61 | 2022-2025 | Rexulti |
| Eisai INC. | $52.33 | 2020-2021 | |
| Bausch Health US, LLC | $51.87 | 2023-2025 | Aplenzin, Wellbutrin |
| Corcept Therapeutics | $47.67 | 2019-2022 | |
| Mylan Specialty L.P. | $44.55 | 2019-2022 | |
| Sanofi Pasteur INC. | $35.32 | 2020-2023 | |
| Horizon Therapeutics Plc | $34.05 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.31 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $30.50 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $30.25 | 2023 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $30.14 | 2022 | |
| Vertos Medical, INC. | $26.83 | 2024 | Mild Device Kit |
| Tactile Systems Technology INC | $22.52 | 2024 | Flexitouch Plus, Entre Plus |
| Alfasigma USA, INC. | $22.24 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.71 | 2024 | Eliquis |
| Genentech USA, INC. | $20.06 | 2020 | |
| Grifols USA, LLC | $20.00 | 2023 | Prolastin-C Liquid |
| Global Blood Therapeutics, INC. | $19.47 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.58 | 2021 | |
| Circassia INC. | $14.42 | 2020 | |
| Krystal Biotech INC | $13.60 | 2023 | Vyjuvek |
| Neurelis, INC. | $13.59 | 2023 | Valtoco |
| Dexcom, INC. | $12.58 | 2021 | |
| Seqirus USA INC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Krasner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.